Skip to content
Back to news
IndustryNovember 15, 2026

Lilly's $3.5B Pennsylvania Obesity Drug Site to Create 850 Jobs

Lilly's $3.5B Pennsylvania Obesity Drug Site to Create 850 Jobs: PharmoniQ news card

Eli Lilly broke ground on Nov. 12 on a $3.5 billion manufacturing site in Fogelsville, in Pennsylvania's Lehigh Valley. The company said the plant will make injectable medicines, including its experimental obesity drug retatrutide, and is expected to create 850 high-wage jobs.

What happened

Lilly announced the start of construction in a news release dated Nov. 12. It said the site should be operational by 2031.

  • Investment: $3.5 billion for the Lehigh Valley plant.
  • Jobs: about 850 high-wage roles for engineers, scientists, operations staff and lab technicians, plus about 2,000 construction jobs during the build, according to the company.
  • Products: injectable medicines, with added capacity for next-generation obesity treatments such as retatrutide.
  • Hiring: Lilly said it is already hiring in the Lehigh Valley.

Retatrutide is a once-weekly shot that acts on three hormone receptors: GIP, GLP-1 and glucagon. It is still being tested in several phase 3 trials and is not approved for sale. Lilly describes it as first-in-class.

The company said the plant will rely on machine learning, AI and data analytics to get each step right the first time. Edgardo Hernandez, who leads Lilly's manufacturing operations, said each production run involves more than 5,000 documented steps. He added that each unit is imaged and inspected more than 70 times for defects. Lilly is also aiming for LEED Gold certification at the site.

Why it matters

The site is one of 10 new US manufacturing sites Lilly has announced since 2020. It is one of four focused on injectable medicines and devices, alongside Kenosha, Wisconsin, and Concord and Research Triangle Park in North Carolina.

BioProcess International reported that Lilly CEO Dave Ricks laid out a plan in February 2025 to spend $27 billion on new US plants. That came on top of $23 billion invested in the US since 2020, for a total commitment of $50 billion.

Because retatrutide is not yet approved, the plant is being built before any regulatory decision on the drug.

Pennsylvania Governor Josh Shapiro called the project a milestone for the state's life sciences sector. Lilly also said it will give up to $1 million over five years for a local health and nutrition program in Upper Macungie Township.

What it means for people in the industry

The plant will need engineers, scientists, operations staff and lab technicians, and Lilly says recruiting has started. For people who work in injectable and device manufacturing, it adds another large employer in Pennsylvania. Timelines can still shift before the 2031 target.

See open pharma jobs in the US and Canada

Sources

Check Your Supplement Interactions

Use our AI-powered checker to analyze supplement safety and interactions.

Open Interaction Checker →

Comments (0)

Leave a comment

Your email is not shown. Please keep it civil and do not give medical advice. Comment rules

This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.